Pharmacopsychiatry 2005; 38(3): 122-124
DOI: 10.1055/s-2005-864122
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Reasons for Switching between Antipsychotics in Daily Clinical Practice

G. W. K. Hugenholtz1 , 2 , E. R. Heerdink2 , W. E. Meijer2 , J.-J. Stolker1 , 2 , A. C. G. Egberts1 , 2 , W. A. Nolen1 , 3
  • 1Altrecht Institute for Mental Health Care, Utrecht, The Netherlands
  • 2Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands
  • 3Department of Psychiatry, University Hospital Groningen, Groningen and University Medical Center Utrecht, Utrecht, The Netherlands
Further Information

Publication History

Received: 8.3.2004 Revised: 16.6.2004

Accepted: 18.10.2004

Publication Date:
18 May 2005 (online)

Background: Previous research that atypical antipsychotics were switched less often compared to typical antpsychotics, suggesting overall better treatment satisfaction. The objective of this study was to investigate the reasons for switching antipsychotics after initiating oral treatment with either typical or atypical antipsychotics in a clinical setting. Patients and Methods: A total of 123 patients that switched antipsychotic therapy were recruited from 17 psychiatric hospitals, of which 46 % switched because of lack of effect and 45 % because of adverse effects. Results: No significant differences were found between users of atypical versus typical antipsychotics in reasons for switching, both for overall adverse events, and lack of effect. In users of atypical antipsychotics extrapyramidal effects were reported less often as reason for switching (adjusted OR = 0.18 (95 % CI = (0.07 - 0.51)). Patients on atypical antipsychotics switched more often because of weight gain (adjusted OR = 12.8 (95 % CI = (1.50 - 109)). Conclusion: In conclusion, when switching occurred, no difference was found in the frequency of general tolerability or reported lack of effectiveness. However, the type of adverse event as a reason for switching differed between atypical and typical antipsychotics.

References

  • 1 Davis J M, Janicak P G, Wang Z, Gibbons R D, Sharma R P. The efficacy of psychotropic drugs: implications for power analysis.  Psychopharmacol Bull. 1992;  28 151-155
  • 2 Leslie D L, Rosenheck R A. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.  Am J Psychiatry. 2002;  159 1534-1540
  • 3 Weiden P J, Aquila R, Dalheim L, Standard J M. Switching antipsychotic medications.  J Clin Psychiatry. 1997;  58 63-72
  • 4 Hugenholtz G W, Heerdink E R, Nolen W A, Egberts A C. Less medication switching after initial start with atypical antipsychotics.  Eur Neuropsychopharmacol. 2004;  14 1-5

Eibert R. Heerdink, PhD

Department of Pharmacoepidemiology and Pharmacotherapy

Utrecht Institute for Pharmaceutical Sciences (UIPS)

PO Box 80082

3508 TB Utrecht

The Netherlands

Phone: +31 30 253 73 24

Fax: +31 30 253 91 66

Email: e.r.heerdink@pharm.uu.nl